Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars, data exclusivity and the TPP: Seeking clarity

This article was originally published in Scrip

Executive Summary

Without the drama of a Rocky movie, the bell rang on the 14th round of the Trans-Pacific Partnership (TPP) on 15th September, with the US heading into the 15th without a proposal for terms of intellectual property protection for brand-name biologics against biosimilars – although sorting out what the American innovator industry is lobbying for in the trade agreement could leave one as dizzy as taking a few punches to the head.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC018773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel